Drug Trial Radar · NCT03694522
A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer
Last checked: Nov 19, 2026Latest source record: Feb 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
155
Actual
Start
Sep 14, 2018
Primary completion
Sep 23, 2020
Study completion May 13, 2022
Sponsor
- Lead sponsor
- Five Prime Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Zai Lab (Shanghai) Co., Ltd.
- First posted
- Oct 3, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of the Phase 2 part of the study is to evaluate the efficacy of bemarituzumab (FPA144), a targeted antibody, in combination with modified FOLFOX6 compared to placebo in combination with modified FOLFOX6 in participants with advanced gastrointestinal cancer.
Conditions
- Gastric Cancer
Interventions
BemarituzumabBiological
Administered by intravenous infusion over approximately 30 minutes
PlaceboDrug
Administered by intravenous infusion over approximately 30 minutes
Modified FOLFOX6Drug
mFOLFOX6 regimen consists of the following: * Oxaliplatin 85 mg/m² IV infusion over 120 minutes * Leucovorin 400 mg/m² IV infusion over 120 minutes, or 200 mg/m² levo-leucovorin if leucovorin is unavailable * 5-fluorouracil (5-FU) 400 mg/m² bolus over approximately 5 minutes then 5-FU 2400 mg/m² as a continuous IV infusion over approximately 48 hours
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: From randomization until the primary analysis data cut-off date of 23 September 2020; median time on follow-up was 10.9 months.
Locations
189 sites in 18 countries. Site status is shown where the registry gives one.
University of Arizona Cancer Center
Tucson, Arizona
The Oncology Institute of Tuscon
Tucson, Arizona
Marin Cancer Care, Inc-California Cancer Care A Medical Group, Inc
Greenbrae, California
Sutter Medical Group
Sacramento, California
UCLA Medical Centre - Santa Monica Hematology and Oncology
Santa Monica, California
Innovative Clinical Research Institute (ICRI)
Whittier, California
Yale Cancer Center
New Haven, Connecticut
Hartford Healthcare Cancer Institute at The Hospital of Central Connecticut
Plainville, Connecticut
University of Chicago
Chicago, Illinois
Northwestern Medicine Cancer Center Warrenville
Warrenville, Illinois
University of Kansas Medical Center
Westwood, Kansas
Oschsner Clinic Foundation
New Orleans, Louisiana
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
University of Michigan Health System
Ann Arbor, Michigan
Karmanos Cancer Institute
Detroit, Michigan
Josephine Ford Cancer Center-Henry Ford Cancer Center
Detroit, Michigan
Summit Medical Group. Morristown Oncology
Morristown, New Jersey
University of Rochester Medical Center (URMC) - Wilmot Cancer Institute (WCI) (James P. Wilmot Cancer Center)
Rochester, New York
Stony Brook Cancer Center
Stony Brook, New York
Westchester Institute For Treatment Of Cancer & Blood Disorders
White Plains, New York
UNC- Chapel Hill
Chapel Hill, North Carolina
FirstHealth Outpatient Cancer Center
Pinehurst, North Carolina
St. Luke's Physician Group - St. Luke's Cancer Care Associates
Bethlehem, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
Tennessee Cancer Specialists
Knoxville, Tennessee
Arlington Cancer Center
Arlington, Texas
Utah Cancer Specialists (Intermountain Hematology - Oncology Associates) UCS Cancer Center
South Salt Lake, Utah
Virginia Mason Seattle Main Clinic
Seattle, Washington
Chris O'brien Lifehouse
Camperdown, Australia
The Townsville Hospital
Douglas, Australia
Sydney Adventist Hospital
Wahroonga, Australia
AZ Sint Jan
Bruges, Belgium
CH de l'Ardenne
Libramont, Belgium
CHC Clinique Saint-Joseph
Liège, Belgium
CHU UCL Namur, site Godinne
Yvoir, Belgium
Beijing Cancer Hospital
Beijing, China
Chinese PLA General Hospital
Beijing, China
The First Hospital of Jilin University
Changchun, China
Sino Japanese Friendship Hospital of Jilin University
Changchun, China
Showing 40 of 189 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.